OPKO Health’s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas
Go back to OPKO Health’s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas| OPKO HEALTH, Inc. (NASDAQ: OPK) | Delayed: 1.43 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.43 | 52 Week High | $11.85 | |||
| Open | $1.43 | 52 Week Low | $7.12 | |||
| Day High | $1.43 | P/E | N/A | |||
| Day Low | $1.43 | EPS | $-0.30 | |||
| Volume | 1,580 | |||||
